CRGD Inhibits Vasculogenic Mimicry Formation by Down-regulating UPA Expression and Reducing EMT in Ovarian Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Mar 19

PMID 26992227

Citations 25

Authors

Jiao Tang

Jianguo Wang

Lin Fan

Xiaoxuan Li

Na Liu

Wanxian Luo

Jihui Wang

Yifeng Wang

Ying Wang

Affiliations

Soon will be listed here.

Abstract

Vasculogenic minicry (VM), an alternative blood supply modality except to endothelial cells-mediated vascular network, is a potential therapeutic target for ovarian cancer due to VM correlated with poor prognosis in ovarian cancer patients. Accelerated extracellular matrix (ECM) degradation is prerequisite for VM formation induced by epithelial-mesenchymal transition (EMT). Previous reports demonstrate uPA has ability to degrade ECM thereby promoting tumor angiogenesis. Also, exogenous cRGD sequence enables to modulate uPA expression, attenuate EMT and suppress endothelial-lined channels. Till now, the correlation of uPA and VM formation and the effect of exogenous cRGD on VM formation remain unknown. Herein, we validate uPA expression is positively correlated with VM formation in ovarian cancer tissues (90 cases) and ovarian cancer cells (SKOV-3, OVCAR-3 and A2780 cells). In particular, silencing uPA experiments show that down-regulated uPA causes notable decrease for the complete channels formed by SKOV-3 and OVCAR-3 cells. Mechanism study discloses uPA promotes VM formation by regulating AKT/mTOR/MMP-2/Laminin5γ2 signal pathway. The result demonstrates uPA may serve as therapeutic target of VM for ovarian cancer. Also, it is found exogenous cRGD enables to inhibit VM formation in ovarian cancer via not only down-regulating uPA expression but also reducing EMT. Exogenous cRGD may be a promising angiogenic inhibitor for ovarian cancer therapy due to its inhibiting effect on VM formation as well as endothelial cells-mediated vascular network.

Citing Articles

A comprehensive analysis of vasculogenic mimicry related genes to predict the survival rate of HCC and its influence on the tumor microenvironment.

Wang J, Gao R, Qi J, Xing Y, Hong B, Wang H Front Genet. 2025; 15:1437715.

PMID: 39748947 PMC: 11693674. DOI: 10.3389/fgene.2024.1437715.

Advance in vasculogenic mimicry in ovarian cancer (Review).

Tian X, Si Q, Liu M, Shi J, Zhao R, Xiong Y Oncol Lett. 2023; 26(4):456.

PMID: 37736556 PMC: 10509778. DOI: 10.3892/ol.2023.14043.

Cancer Three-Dimensional Spheroids Mimic In Vivo Tumor Features, Displaying "Inner" Extracellular Vesicles and Vasculogenic Mimicry.

Giusti I, Poppa G, DAscenzo S, Esposito L, Vitale A, Calvisi G Int J Mol Sci. 2022; 23(19).

PMID: 36233083 PMC: 9569704. DOI: 10.3390/ijms231911782.

Vitamin D Exerts Significant Antitumor Effects by Suppressing Vasculogenic Mimicry in Breast Cancer Cells.

Bajbouj K, Al-Ali A, Shafarin J, Sahnoon L, Sawan A, Shehada A Front Oncol. 2022; 12:918340.

PMID: 35747793 PMC: 9210804. DOI: 10.3389/fonc.2022.918340.

Self-anti-angiogenesis nanoparticles enhance anti-metastatic-tumor efficacy of chemotherapeutics.

Luo J, Zhong X, Peng Y, Hao C, Liang X, Yang Y Bioact Mater. 2022; 13:179-190.

PMID: 35224300 PMC: 8843953. DOI: 10.1016/j.bioactmat.2021.10.037.

References

Dobbin Z, Landen C . The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 2013; 14(4):8213-27. PMC: 3645739. DOI: 10.3390/ijms14048213. View

Ren K, Yao N, Wang G, Tian L, Ma J, Shi X . Vasculogenic mimicry: a new prognostic sign of human osteosarcoma. Hum Pathol. 2014; 45(10):2120-9. DOI: 10.1016/j.humpath.2014.06.013. View

Cai L, Lyu X, Luo W, Cui X, Ye Y, Yuan C . EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. Oncogene. 2014; 34(17):2156-66. DOI: 10.1038/onc.2014.341. View

Gao N, Zhang Z, Jiang B, Shi X . Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun. 2003; 310(4):1124-32. DOI: 10.1016/j.bbrc.2003.09.132. View

Ju R, Li X, Shi J, Li X, Sun M, Zeng F . Liposomes, modified with PTD(HIV-1) peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials. 2014; 35(26):7610-21. DOI: 10.1016/j.biomaterials.2014.05.040. View

Miyazono K, Heldin C . Latent forms of TGF-beta: molecular structure and mechanisms of activation. Ciba Found Symp. 1991; 157:81-9; discussion 89-92. DOI: 10.1002/9780470514061.ch6. View

Wang W, Lin P, Sun B, Zhang S, Cai W, Han C . Epithelial-mesenchymal transition regulated by EphA2 contributes to vasculogenic mimicry formation of head and neck squamous cell carcinoma. Biomed Res Int. 2014; 2014:803914. PMC: 4016880. DOI: 10.1155/2014/803914. View

Sun B, Zhang S, Zhao X, Zhang W, Hao X . Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol. 2004; 25(6):1609-14. View

Wang L, Madigan M, Chen H, Liu F, Patterson K, Beretov J . Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Gynecol Oncol. 2009; 114(2):265-72. DOI: 10.1016/j.ygyno.2009.04.031. View

10.

Mi Z, Guo H, Wai P, Gao C, Kuo P . Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis. 2006; 27(6):1134-45. DOI: 10.1093/carcin/bgi352. View

11.

Fan Y, Zheng M, Tang Y, Liang X . A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review). Oncol Lett. 2013; 6(5):1174-1180. PMC: 3813799. DOI: 10.3892/ol.2013.1555. View

12.

Bellocq J, Luporsi E, Barriere J, Bonastre J, Chetritt J, Le Corroller A . [uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management]. Ann Pathol. 2014; 34(5):349-51. DOI: 10.1016/j.annpat.2014.04.010. View

13.

Parvani J, Gujrati M, Mack M, Schiemann W, Lu Z . Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer. Cancer Res. 2015; 75(11):2316-2325. PMC: 4452414. DOI: 10.1158/0008-5472.CAN-14-3485. View

14.

Yang Z, Sun B, Li Y, Zhao X, Zhao X, Gu Q . ZEB2 promotes vasculogenic mimicry by TGF-β1 induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Exp Mol Pathol. 2015; 98(3):352-9. DOI: 10.1016/j.yexmp.2015.03.030. View

15.

Liu Z, Sun B, Qi L, Li H, Gao J, Leng X . Zinc finger E-box binding homeobox 1 promotes vasculogenic mimicry in colorectal cancer through induction of epithelial-to-mesenchymal transition. Cancer Sci. 2012; 103(4):813-20. PMC: 7659366. DOI: 10.1111/j.1349-7006.2011.02199.x. View

16.

Sood A, Fletcher M, Coffin J, Yang M, Seftor E, Gruman L . Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol. 2004; 190(4):899-909. DOI: 10.1016/j.ajog.2004.02.011. View

17.

Liu K, Sun B, Zhao X, Wang X, Li Y, Qiu Z . Hypoxia promotes vasculogenic mimicry formation by the Twist1-Bmi1 connection in hepatocellular carcinoma. Int J Mol Med. 2015; 36(3):783-91. DOI: 10.3892/ijmm.2015.2293. View

18.

Maniotis A, Folberg R, Hess A, Seftor E, Gardner L, Peer J . Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999; 155(3):739-52. PMC: 1866899. DOI: 10.1016/S0002-9440(10)65173-5. View

19.

Liu X, Wang J, Li S, Li L, Huang M, Zhang Y . Histone deacetylase 3 expression correlates with vasculogenic mimicry through the phosphoinositide3-kinase / ERK-MMP-laminin5γ2 signaling pathway. Cancer Sci. 2015; 106(7):857-66. PMC: 4520637. DOI: 10.1111/cas.12684. View

20.

Zhang W, Ling D, Tan J, Zhang J, Li L . Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance. Oncol Rep. 2012; 29(2):637-45. DOI: 10.3892/or.2012.2148. View